格列卫治疗20例慢性粒细胞白血病临床观察  

CLINICAL OBSERVATION OF 20 CHRONIC MYELOGENOUS LEUKEMIA WITH GLEEVEC

作　　者：赵耀中[1] 邹德慧[1] 靳风艳[1] 徐燕[1] 隋伟薇[1] 刘凯奇[1] 方力维 董树旭 孙明媛[1] 刘薇 陈芳[1] 钱林生[1] 邱禄贵 

机构地区：[1]中国医学科学院,中国协和医科大学血液学研究所,血液病医院血液内科,天津300020

出　　处：《白血病．淋巴瘤》2004年第2期65-67,共3页Journal of Leukemia & Lymphoma

摘　　要：目的:评价格列卫治疗慢性粒细胞白血病(CML)的效果和不良副作用。方法:CML慢性期(CP)患者口服格列卫400 mg/d。CML加速期、急变期(BC)患者口服格列卫400 mg^600 mg/d。结果:11例CML蛳CP患者均取得血液学完全缓解(HCR)。9例CML蛳AP和CML蛳BC患者4例取得HCR(37 %)。7例CML蛳CP患者在3 个月~ 6 个月内4例取得遗传学完全缓解(56 %)。CML蛳CP患者Ⅲ级白细胞(WBC)减少1例,血小板(BPC)减少2例。CML蛳AP和CML蛳BC患者,4例发生Ⅲ级~Ⅳ级WBC减少和BPC减少。而非血液学不良副作用,无Ⅲ级或Ⅳ级以上的毒副作用。结论:格列卫治疗CML蛳CP具有较高的HCR和细胞遗传学反应,CML蛳BC患者亦可取得较好的血液学反应。格列卫不良副作用发生率低,尤其CML蛳CP患者为安全,而CML蛳AP和CML蛳BC患者治疗期间,需加强支持治疗。Objective: To evaluate the efficacy and side effect of Gleevec in the treatment of patients with chronic myelogenous leukemia in chronic phase (CP),accelerated phase (AP) and blast crisis (BC). Methods: CML- CP patients and CML- AP or CML- BC patients were respectively treated with 400 mg/d and 400 mg/d^600 mg/d of oral Gleevec. Results: All eleven patients (100 %) with CML- CP and four of nine patients (37 %) with CML- AP and CML- BC achieved complete hematological response. Four of seven patients (56 %) achieved complete cytogenetic response between 3 and 6 months. Grade 3 leukopenia and thrombocytopenia respectively occurred in one and two patients with CML- CP. Grade 3 to grade 4 leukopenia and thrombocytopenia occurred in four patients with CML- AP and CML- BC. Grade 3 or 4 nonhematologic adverse effects were infrequent. Conclusion: Gleevec induced high rate of hematologic responses and cytogenetic responses in CML- CP patients. Meantime, Gleevec reached better hematologic responses in CML- BC patients. Furthermore, the adverse effects were mild, especially, CML- CP patients. Supporting treatment should strengthen in CML- AP or CML- BC patients during taking Gleevec.

关 键 词：格列卫 慢性白血病 髓系 

分 类 号：R733.72[医药卫生—肿瘤]